Pinkerton JV - Search Results

1

Perspective on menopausal vasomotor symptoms, CAM, and the SWAN.

Pinkerton JV, Pastore LM. Pinkerton JV, et al. Menopause. 2007 Jul-Aug;14(4):601-5. doi: 10.1097/GME.0b013e318064e8c4. Menopause. 2007. PMID: 17529901 No abstract available.

2

Acceptance of fragile X premutation genetic screening in women with ovarian dysfunction.

Pastore LM, Karns LB, Pinkerton JV, Silverman LM, Williams CD, Camp TR. Pastore LM, et al. Among authors: pinkerton jv. Am J Obstet Gynecol. 2006 Mar;194(3):738-43. doi: 10.1016/j.ajog.2005.10.218. Am J Obstet Gynecol. 2006. PMID: 16522406

3

Triple repeat diseases and unstable gonadal function.

Pastore LM, Pinkerton JV, Williams CD. Pastore LM, et al. Among authors: pinkerton jv. Fertil Steril. 2007 Nov;88(5):1477; author reply 1477. doi: 10.1016/j.fertnstert.2007.07.023. Fertil Steril. 2007. PMID: 17991519 Free article. No abstract available.

4

The effects of abuse on health problems in menopausal women.

Pinkerton JV, Dougherty P, Modesitt SC. Pinkerton JV, et al. Menopause. 2008 Jan-Feb;15(1):1-4. doi: 10.1097/gme.0b013e31815b89ec. Menopause. 2008. PMID: 18090873 No abstract available.

5

Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk?

Pinkerton JV, Stovall DW. Pinkerton JV, et al. Menopause. 2009 Mar-Apr;16(2):219-23. doi: 10.1097/gme.0b013e318199404a. Menopause. 2009. PMID: 19188853 Review. No abstract available.

6

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.

Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Pinkerton JV, et al. Menopause. 2009 Nov-Dec;16(6):1116-24. doi: 10.1097/gme.0b013e3181a7df0d. Menopause. 2009. PMID: 19546826 Clinical Trial.

7

Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.

Pinkerton JV, Constantine G, Hwang E, Cheng RF; Study 3353 Investigators. Pinkerton JV, et al. Menopause. 2013 Jan;20(1):28-37. doi: 10.1097/gme.0b013e31826421a8. Menopause. 2013. PMID: 23010882 Clinical Trial.

8

Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.

Pinkerton JV, Archer DF, Guico-Pabia CJ, Hwang E, Cheng RF. Pinkerton JV, et al. Menopause. 2013 Jan;20(1):38-46. doi: 10.1097/GME.0b013e318274699f. Menopause. 2013. PMID: 23266839 Clinical Trial.

9

Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.

Archer DF, Pinkerton JV, Guico-Pabia CJ, Hwang E, Cheng RF; Study 3353 Investigators. Archer DF, et al. Among authors: pinkerton jv. Menopause. 2013 Jan;20(1):47-56. doi: 10.1097/gme.0b013e3182775fe9. Menopause. 2013. PMID: 23266840 Clinical Trial.

10

Risk of first-time heart disease higher for hormone therapy users with metabolic syndrome.

Pinkerton JV, Pastore LM, Johns DW, Tucker AL. Pinkerton JV, et al. Menopause. 2013 Mar;20(3):244-7. doi: 10.1097/GME.0b013e3182850c5d. Menopause. 2013. PMID: 23435018 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page